**CURRICULUM VITAE**

**Augusto A. Miravalle, M.D.**

**Current Rank:** Associate Professor

**Academic Office:** University of Colorado School of Medicine

12631 East 17th Avenue, Room 5507 Mail Stop B185

Aurora, Colorado 80045

**Research Address**: University of Colorado Hospital Anschutz Outpatient Pavilion

1635 Aurora Court, 5th floor

Aurora, Colorado 80045

University of Colorado Hospital Leprino Building

12401 East 17th Avenue

Aurora, Colorado 80045

1. **EDUCATION:** (Residency, fellowship or graduate school training)

|  |  |  |
| --- | --- | --- |
| **School/Program** | **Degree** | **Dates** |
| **Universidad Nacional de La Plata**  Argentina | MD | 1995 to 2001 |
| **Resurrection-Westlake Hospital**  Melrose Park, Illinois | Internship in Internal Medicine | 2004 to 2005 |
| **Loyola University Medical Center/Hines VA Hospita**l, Chicago, Illinois | Residency, Neurology | 2005 to 2008 |
| **Harvard University/Beth Israel Deaconess Medical Center,** Boston, MA | Multiple Sclerosis Clinical Fellowship | 2008 to 2009 |
| **Harvard University/Brigham and Women’s Hospital,** Boston, MA | Laboratory for Neuroimaging Research, Neuroimaging Research Fellow | 2008 to 2009 |
| **University of Rochester**  Rochester, NY | American Neurological Association’s Neurology Teaching Scholarship Program | 2012 |

1. **PROFESSIONAL EXPERIENCE:**

***Academic Appointments***

|  |  |  |
| --- | --- | --- |
| **Institution** | **Rank** | **Dates** |
| **University of Colorado, Department of Neurology** | Assistant Professor of Neurology | 2009—2014 |
| **University of Colorado, Department of Neurology** | Associate Residency Program Director | 2011—2013 |
| **University of Colorado, Department of Neurology** | Program Director, Neurology Residency Program | 2013—Present |
| **University of Colorado, Department of Neurology** | Associate Professor of Neurology | 2014 - Present |
| **University of Colorado, Department of Neurology** | Vice-Chair for Education | 2014 – Present |

***Hospital Positions***

|  |  |  |
| --- | --- | --- |
| **Institution** | **Position** | **Dates** |
| **University of Colorado Hospital,**  Aurora, CO | Active Staff | 2009—Present |
| **Parkview Medical Center,** Pueblo, CO | Active Staff | 2009--2011 |
| **St. Mary-Corwin Medical Center,** Pueblo, CO | Active Staff | 2009—2011 |
| **The Children’s Hospital Colorado,** Aurora, CO | Active Staff | 2011—Present |
| **Metro Community Providers Network,** Aurora, CO | Active Staff | 2011—Present |

1. **HONORS, AWARDS AND RECOGNITIONS**

**Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina**

Award for “Best Teaching Assistant”. In recognition of the significant contributions to

education and patient care. Department of Internal Medicine 1999

Highest Academic distinction. 2001

Cumulative final grade, Medical School: 9.38/10.0 2002

**Loyola University Medical Center, Chicago, IL**

Frank A. Rubino Clinical Neurology Award. In recognition for excellence in patient care and education in the art and science of Neurology 2007

Housestaff Magis Spirit Award. 2008

Voted to “Best Doctors” list, by the *Denver Business Journal*  October, 2012

Named to “Best Doctors in America” 2013

1. **EXAMINATIONS**

* USMLE Step 1 Passed August, 2002
* TOEFL Passed November, 2002
* USMLE Step 2 Passed November, 2002
* ECFMG CSA Passed February, 2003
* USMLE Step 3 Passed December, 2006

1. **PUBLIC AND UNIVERSITY SERVICE ACTIVITIES/PROFESSIONAL SOCIETY MEMRSHIP/HONORS:**

|  |  |
| --- | --- |
| 2009—Present | Neurology Residency Faculty Mentor Committee |
| 2010—Present | Neurology Residency Selection Committee |
| 2010—Present | Neurology Hospitalist Program Committee |
| 2010—Present | School of Medicine Admissions Committee |
| 2011—Present | Neurology Residency Education Curriculum Committee |
| 2011—2013 | Clinical Competency Committee |
| 2011—Present | Editorial Board Guest editor, *Multiple Sclerosis International,* Reviewer, *Journal of Stroke and Cerebrovascular Diseases*, *Dove Medical Press* |
| 2012—Present  2012—Present | Neurology Performance Improvement Committee  Supervisor Resident Continuity Clinic, UCH |
| 2011—Present | American Academy of Neurology*-Member-*  Colorado Society of Clinical Neurologists*-Member-*  American Neurological Association*-Member-* |
| 2013—Present | Clinical Competency Committee (CHAIR) |

**6. LICENSURE AND BOARD CERTIFICATION**

* State of Colorado 2008—Present
* State of Massachusetts 2008—2009
* State of Illinois 2007—2008
* Board Certification, American Board of Psychiatry and Neurology 2008— Present

1. **TEACHING ACTIVITIES:**

***INVITED LECTURES AND PRESENTATIONS – NATIONAL***

* Low Dose Rituximab Protocol for Patients with RRMS. Presented at American Academy of Neurology Meeting, Seattle, WA, April, 2009
* Immune Reconstitution Inflammatory Syndrome after Discontinuation of Natalizumab Therapy in MS Patients. Presented at the 14th Annual Meeting of ACTRIMS, Atlanta, GA. May, 2009
* Advanced Studies in Medicine web presentation, Updates on MS Therapies, Houston, Tx 2010
* Projects in Knowledge webcasts at the American Academy of Neurology annual meeting, Hawaii, March, 2011
* Advanced Studies in Medicine presentation, Updates on MS Therapies, Chicago, Il 2011
* Advances Studies in Medicine Continuing Education webcast, “The Clinical Challenges of Multiple Sclerosis: Managed Care and Specialty Pharmacist Perspectives” , July, 2012
* Webcast for Advanced Studies in Medicine (ASiM), continuing professional education series, *The Clinical Challenges of Multiple Sclerosis: Managed Care and Specialty Pharmacist Perspectives* October 8, 2012
* Webcast for Advanced Studies in Medicine (ASiM) continuing professional education series, Boulder, CO, October 25, 2012
* Use of PBL and Simulation to capture Milestones data. ACGME conference, Washington, DC, February 2014

***INVITED LECTURES - REGIONAL***

* Conversation in MS, Rocky Mountain MS Center Presentation, Pueblo, CO January, 2010
* *MRI in MS: from papers to practice* presentation to Colorado Neurological Society, February, 2010
* *Biomarkers in MS*. Rocky Mountain MS Center Research Conference. Fort Collins, CO. April, 2011
* Rocky Mountain MS Center Research Seminar presentation, Colorado Springs, CO October, 2011
* *Update on MRI in MS*. Rocky Mountain MS Center Research Conference. Aurora, CO. November, 2011
* *PML in MS* presentation to the Colorado Neurological Society, November, 2011
* Presentation to Colorado Springs Neurological Associates, January 12, 2012
* Rocky Mountain MS Center Research Update Seminar, Denver, CO April, 2012
* Rocky Mountain MS Center *Managing MS Symptoms for Maximum Wellness* Denver, CO,

May, 2012

* Presenting faculty member, “ Epidemiology and Pathophysiology of MS” presentation given at Advanced Studies in Medicine (ASiM) seminar entitled *The Clinical Challenges of Multiple Sclerosis: Managed Care and Specialty Pharmacist Perspectives,* Boulder, CO July, 2012
* *Risk Mitigation and Safety Considerations when Choosing Multiple Sclerosis Treatments* presentation given to Movement Disorders and Multiple SclerosisSeminar, Denver, CO. September, 2012
* Rocky Mountain MS Center Providers Summit, Westminster, CO October, 2012.
* Rocky Mountain MS Center *The Future of MS Diagnosis, Monitoring and Risk Mitigation*  seminar presentation: “New Diagnostic Techniques and Resources Provide Better diagnostic Information and Can better Guide Treatment Decisions and Risk Assessment. Westminster, Co November 3, 2012
* Prospects of Repair in MS. Colorado Society for Clinical Neurologists. March 2014

1. **TEACHING RECORD:**

***Presentation to Medical Students and Residents***

* Mitochondrial Disorders. Adult presentation of Leigh’s disease. Case report and review of the literature. Grand Rounds Loyola University Medical Center Stritch School of Medicine, Department of Neurology, Maywood, Ill August, 2005
* Benedict syndrome. Case report and review of the literature. Grand Rounds, Loyola University Medical Center Stritch School of Medicine, Department of Neurology, July, 2006
* Leukodystrophies. Loyola University Medical Center Stritch School of Medicine, Department of Neurology, August, 2006
* Nemaline Rod Myopathy. Case report and review of the literature. Clinicopathological Conference. Loyola University Medical Center Stritch School of Medicine, Department of Neurology. October, 2006
* ADEM, AHLE and Postinfectious Encephalomyelitis. Loyola University Medical Center Stritch School of Medicine, Department of Neurology. January, 2007
* Infectious Disorders of the CNS. Selective CNS Complications. Grand Rounds, Loyola University Medical Center Stritch School of Medicine, Department of Neurology. June, 2007
* Radiation Induced Frontal Lobe Atypical Meningioma. Clinico-Pathological Conference, Loyola University Medical Center Stritch School of Medicine, Department of Neurology. July, 2007
* Infectious CNS Vasculitis. Grand Rounds, Loyola University Medical Center Stritch School of Medicine, Department of Neurology. November, 2007
* Viral Hemorrhagic Fevers and Other CNS Infections in the International Traveler. Grand Rounds, Loyola University Medical Center Stritch School of Medicine, Department of Neurology. November, 2007
* Clinical Neurology. Board Review, Loyola University Medical Center Stritch School of Medicine, Internal Medicine Department. March, 2008
* ADEM Complicating Yellow Fever vaccination. Loyola University Medical Center Stritch School of Medicine, Department of Neurology. May, 2008
* Role of B Cells in MS. Department of Neurology, University of Colorado. October, 2008
* Emerging MRI Techniques in MS. Beyond White Matter Lesions. Latest Advances in the Treatment of MS. Inverness Hotel, Englewood, CO. November, 2009
* Spinal Cord Disorders—From Neuroanatomy to Clinical Cases. Department of Neurology, University of Colorado. August, 2010
* Clinical Case Conference. Neuroimmunology. Department of Neurology, University of Colorado. October, 2010
* Multiple Sclerosis as a Model for the Neurophysiological Disorder. Molecules to Medicine, Department of Physiology, University of Colorado. November, 2010
* Biomarkers in Multiple Sclerosis. Department of Neurology, University of Colorado. December, 2010
* Brainstem Syndromes. Localization in Clinical Neurology review. Department of Neurology, University of Colorado. January, 2011
* Grand Rounds presentation, Department of Neurology, University of Colorado “Paradoxes in MS: A Review From a Clinical Perspective” March 9, 2011.
* Updates on the American Academy of Neurology meeting. MS Therapies. Department of Neurology, University of Colorado. April, 2011
* MRI in MS. Case Presentation and Review of Emerging MRI Techniques. Department of Neurology, University of Colorado. October, 2011
* MS as a Model of Demyelination. Molecules to Medicine, Department of Physiology, University of Colorado. November, 2011
* RITE Exam Review. MS and CNS Demyelinating Disorders. Department of Neurology, University of Colorado
* MS 101. Clinical Research Group, University of Colorado. February, 2012
* Paradoxes in MS. Neuropsychology Group, Department of Neurosurgery, University of Colorado. February, 2012
* SABES Spanish Speaking teaching session, CAPE, University of Colorado School of Medicine

January 20, 2012

* Neuroinflammation block lecture, “Emergency Neurology, July 11, 2012
* Teaching Fellow, 2nd year neural science course, “Mind, Brain and Behavior”, University of Rochester Medical Center, Rochester, NY, September, 2012
* Molecules to Medicine lecture, *Multiple Sclerosis Vignettes*, University of Colorado School of Medicine November 19, 2012
* Grand Rounds University of Colorado Department of Neurology, “Neuroimmunology: Challenging Dilemmas of Common Clinical Presentations”. January 23, 2013
* RITE exam review sessions (monthly). Department of Neurology, Residency Program. July 2013 to present
* Neuroradiology Conferences (monthly). Department of Neurology, Residency Program. July 2013 to present
* Grand Rounds University of Colorado Department of Neurology, “Updates in MS: Five new things”. January, 2014
* Grand Rounds University of Colorado Department of Neurology, “Prospects on Repairs in MS”. March, 2014

1. **EDITORSHIPS**

* Guest editor, “Imaging Gray Matter Disease in Multiple Sclerosis” for*Multiple Sclerosis International*
* Reviewer, *Journal of Stroke and Cerebrovascular Diseases* 2012 to present
* Reviewer, Dove Medical Press 2012 to present

1. **GRANT SUPPORT – CURRENT:**

***CLINICAL TRIALS participating as PRINCIPAL INVESTIGATOR (PI)***

|  |  |  |
| --- | --- | --- |
| **Grant Support – Current – Primary Investigator** | | |
| **Name/Description** | **Date** | **Total Award** |
| **Accelerated Cure Project**. (PI)  A study to collect medical and epidemiological data and blood samples for research into the causes of  MS and selected demyelinating diseases | 02/17/2009-02/16/2015 | $301,700 |
| **Biogen** DECIDE.  (PI) A study to determined the efficacy and safety of daclizumab high yield process versus Avonex in patients with RRMS | 09/15/2010 – 10/29/2015 | $493,483 |
| **Biogen** ASCEND.  (PI) A study of the efficacy of natalizumab on reducing disability in subjects dieth secondary progressive MS | 08/01/2011 - 07/31/2014 | $491,782 |
| **Roche** ORATORIO. (PI)  A study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive MS | 01/01/2011 – 09/30/2015 | $1,444,643 |
| **Roche** ORCHESTRA. (PI) A study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon B1(Rebif) in patients with relapsing remitting MS | 03/01/2012-02/28/2015 | $737,882 |
| **Teva** GALA.  (PI) A study performed in subjects with relapsing remitting MS assessing the efficacy, safety and tolerability of glatiramer acetate | 06/15/2010—06/14/2016 | $120,740 |
| **Xenoport**. (PI)  An efficacy and safety study of arbaclofen placarbil in subjects with spasticity due to MS | 10/31/2011 – 07/31/2014 | $305,392 |
| **Xenport** open label extension study.  (PI) A 26-week study to assess arbaclofen placarbil  in subjects with spasticity due to MS | 08/24/2011-09/14/2014 | $357,255 |
| **OSMOTICA** (PI)  To compare the efficacy and safety of arbaclofen extended release oral medication to placebo in subjects to spasticity due to MS. | 02/25/2013-02/24/2016 | $103,984 |
| **NINDS/NeuroNEXT  Ibudilast** (PI) To evaluate the safety and tolerability of ibudilast versus placebo in subjects with primary progressive MS and secondary progressive MS | 11/01/2013-10/31/2016 | $151,880 |

***CLINICAL TRIALS participating as Co-INVESTIGATOR***

|  |  |  |
| --- | --- | --- |
| **Title/Description** | **Sponsor** | **Role** |
| **ELND002-MS103.** A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patient with Relapsing Forms of MS. | Elan Pharmaceuticals | Co-Investigator |
| **NADS.** A Single-arm, Two-period, Cross-over, Phase IIb Trial of an Alternative dosing Strategy for Natalizumab. | Biogen Idec. | Co-Investigator |
| **STRATIFY-1.** JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri. | Biogen Idec. | Co-Investigator |
| **MARBLE.** Myxovirus-Resistant Protein A as a Measure of Clinical Efficacy of Interferon-Beta Treatment in Patients with Multiple Sclerosis | Biosite | Co-Investigator |
| **BCDJ.** Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing Remitting Multiple Sclerosis. | Eli Lilly and Co. | Co-Investigator |
| **ACP.** A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases. | Accelerated Cure Project | Co-Investigator |
| **TYGRIS.** Tysabri® Global Observational Program in Safety. | Biogen Idec | Co-Investigator |
| **Oracle**. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trail of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS. | Serono | Co-Investigator |
| **CFTY720D2306**. A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis. | Novartis | Co-Investigator |
| **BRAVO.** A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in double-blind design and of a reference arm of Interferon B-1a (Avonex®) in a rater-blinded design. | Teva Neuroscience. | Co-Investigator |
| **F1J-US-HMFR**. Duloxetine in Patients with Central Neuropathic Pain Due to Multiple Sclerosis. | Eli Lilly and Co. | Co-Investigator |
| **CombiRx-Phase III.** A Multi-Center, Double-Blind, Randomized Study Comparing the Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with MS. | NIH/NINDS | Co-Investigator |

1. **GRANT SUPPORT - PAST**

**Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina**

Miravalle A, Belloni R, Suarez I, Giacommantone O. Relationship between BMI and hypertension in the hospital population. Description: Prospective study in outpatient population admitted to internal Medicine Department during the1009-2000 year period. Presented at the XII Internal Medicine Meeting – La Plata, Bs. As. Argentina, May, 2000

**Indiana University Medical Center, Department of Neurology, Indianapolis, IN**

Miravalle A, Roos KL. Encephalitis complicating smallpox vaccination.

Description: Review of the literature and analysis of potential consequences of smallpox infection as

a biological weapon. Indianapolis, November 2002.

**Loyola University Medical Center, Department of Neurology, Maywood, IL.**

Miravalle A, Biller J. Infectious causes of stroke. October 2003. Description: Case series, review of the

literature. Cerebrovascular disease complicating systemic and CNS infections.

Miravalle A, Farrer R, Javed A, Kartje G. Nogo-A protein in MS patients. July 2007. Description: Cross section and longitudinal analysis of presence of Nogo-A protein and anti Nogo-A antibodies in serum, CSF, and brain samples of patients with MS. Quantification of antibodies. Identification and sequence of Nogo-A protein and derived peptides. Techniques involved: Western blot, ELISA

**Harvard University.** **Brigham and Women’s Hospital. Boston, MA USA**

Miravalle A, Neema M, Bakshi R. Clinical MRI-MS Imaging Center. T2 relaxometry, R2 and R2\* analysis in RRMS patients.

1. **BIBLIOGRAPHY**

***Bibliography-Peer Reviewed Journal Articles***

1. **Miravalle A**, Roos KL. Encephalitis complicating smallpox vaccination. *Arch Neurol.* Jul 2003;60(7):925-928.
2. **Miravalle A**, Biller J, Silva E, Conneely M, O'Keefe P. Acute disseminated encephalomyelitis: yellow fever vaccination. *Arq Neuropsiquiatr.* Sep 2009;67(3A):710-711.
3. **Miravalle A.** Ramsay Hunt Syndrome. *E-medicine*. August 2009
4. **Miravalle A.** Lyme Disease. Neuroborreliosis. *E-medicine*. July 2009
5. **Miravalle A.** Neurodegeneration: The clinical evidence. *Adv Stud Pharm*. 2010;7(3):57-62
6. **Miravalle A,** Bennett J. Recent advances in the treatment of multiple sclerosis. *J of exp pharm* 2010:2;155-161
7. Corboy JR, **Miravalle AA**. Emerging therapies for treatment of multiple sclerosis. *J Inflamm Res.* 2010;3:53-59.
8. **Miravalle A**, Biller J, Schnitzler E, Bonwit A. Neurological complications following vaccinations. *Neurol Res.* Apr 2010;32(3):285-292.
9. Berger JR, Comi G,Confavreux C, Lublin F, **Miravalle A**, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. *Ann Neurol.* Sep 2010;68(3):409-411.
10. **Miravalle A**, Corboy JR. Therapeutic options in multiple sclerosis: five new things. *Neurology.* Nov 2 2010;75(18 Suppl 1):S22-27.
11. **Miravalle A**, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. *Arch Neurol.* Feb 2011;68(2):186-191.
12. Kala M, **Miravalle A**, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. *J Neuroimmunol.* Jun 2011;235(1-2):9-17.
13. **Miravalle A**, Hendin B, Vollmer T, Kala M. Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis. *Clin Med Insights: Therapeutics*. 2011:3 151—158
14. **Miravalle AA**. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. *Am J Manag Care.* May 2011;17 Suppl 5 Improving:S154-160.
15. Nielsen AS, **Miravalle A**, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. *Mult Scler.* Mar 2012;18(3):377-378.
16. West MS, **Miravalle A**. Profile of oral laquinimod and its potential in the treatment of multiple sclerosis. *Degenerative Neurological and Neuromuscular Disease.* 2012:1;25—32
17. Schreiner T. **Miravalle A**. Current and emerging therapies for the treatment of multiple sclerosis: Focus on cladribine. *J of Central Nervous System Disease.* 2012 2012;4:1--14.
18. Kleinschmidt-DeMasters BK, **Miravalle A**, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. *J of neuropathol Exp Neurol.* 2012 71:7 July 2012 604-617.
19. Cambell J, McQueen B, **Miravalle A**, Corboy J, Vollmer T, Nair K. Comparative Effectiveness of Early Natalizumab Treatment in JC Virus-Negative Relapsing-Remitting Multiple Sclerosis. *Am J Manag Care.* 2013: 19(4): 278-285.

***Bibliogrpahy-Peer Reviewed Publication—In press/accepted for publication/submitted***

1. Selmaj K, Zipp, F, Bar-Or A, **Miravalle A**, Due, B, Vollmer T on behalf of the DreaMS study group. A randomized trial of ONO-4641 in Relapsing-Remitting Multiple Sclerosis. Submitted to *New England Journal of Medicine* June, 2013
2. Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Linvingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K. Burden of Multiple Sclerosis on Direct, Indirect Costs and Quality of Life: National US Estimates. Accepted for publication in *Multiple Sclerosis and Related Disorders* September, 2013

***Biblography-Books/chapters***

1. Roos KL, **Miravalle A**. Postinfectious Encephalomyelitis. Infections of the Centeral Nervous System. Scheld WM, Whitley RJ, Marra C. Third edition. Lippincott Williams & Wilkins, Philadelphia 2004
2. **Miravalle A**. Corbett J. Biller J. Infectious Casues of Stroke. Interface of Neurology and Internal Medicine. Biller J. First edition. Lippincott Williams & Wilkins, Philadelphia 2007
3. **Miravalle A**, Schreiner T. Neurological complications of vaccinations. Neurological aspects of systemic disease. Handbook of Clinical Neurology. Biller J, Ferro M. Elsevier 2013
4. Roos KL, **Miravalle A**. Postinfectious Encephalomyelitis. Infections of the Centeral Nervous System. Scheld WM, Whitley RJ, Marra C. Third edition. Lippincott Williams & Wilkins, Philadelphia 2013

***ABSTRACTS AND POSTER PRESENTATIONS***

1. Campbell J, Ghushchyan V, McQueeen RB, Cahoon-Metzger S, Pang-Linvingston T, Vollmer T, Corboy J, **Miravalle A**, Schreiner T, Nair, K. Direct Costs, Indirect Costs, and Quality of Life Burden of Multiple Sclerosis: National US Estimates. Abstract and poster presentation at the American Academy of Neurology annual meeting, San Diego, CA March 19, 2013
2. **OTHER AWARDS AND ACCOMPLISHMENTS**

**Discography**

**Muzio Clementi – Works for Piano –Quadromania – 4 CDs. 1990**

* Piano Sonato No. 5 in F Major, Op. 4

Augusto Miravalle (piano)

* Piano Sonato No. 6 in B Flat Major, op. 4

Augusto Miravalle (piano)

**Musical Education**

Piano Master Classes:

* Rosalyn Tureck, New York, 1990
* Ralph Votapeck, Buenos Aires, 1991
* Lazar Berman, Buenos Aires, 1993
* Emille Naoumoff, Madrid, 1994

**Performances and Piano Competitions:**

* National Piano Competition “Festivales Musicales”

Second place, Silver medal. Buenos Aires, Argentina. September, 1994

* International Piano Competition.

First place, Gold medal Cordoba, Argentina, October, 1987

* Gina Bachauer International Piano Competition, Salt Lake City Utah, 1990

Selected to participate in semifinals

**Orchestra Performances:**

* Cordoba Symphony Orchestra, Cordoba, Argentina

Mendelsshohn’s Piano Concerto N1 G Minor. 1998

* San Martin Symphony Orchestra, Buenos Aires, Argentina

Mozart’s Piano Concerto N3 in D Major, K. 40. 1990

* La Plata Chamber Orchestra, La Plata, Argentina

Mozart’s Piano Concerto N3 in D Major, K. 40. 1990